{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:43:18Z","timestamp":1790178198846,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,20]],"date-time":"2024-01-20T00:00:00Z","timestamp":1705708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,20]],"date-time":"2024-01-20T00:00:00Z","timestamp":1705708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007797","name":"University of Helsinki","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007797","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Reprod Biol Endocrinol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Erythropoietin (Epo) is a potent vascular growth factor that induces angiogenesis and antiapoptotic signalling. We investigated whether the development of numerous follicles and corpora lutea during in vitro fertilization (IVF) cycle affects circulating Epo levels and further, if Epo could be used as a novel marker for ovarian hyperstimulation syndrome (OHSS).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>24 women were included in the uncomplicated IVF group and 35 women in the OHSS group. Repeated blood samples from both groups were analysed for Epo, progesterone, blood haemoglobin, and creatinine. Follicular fluid from the IVF group was analysed for Epo and progesterone. Repeated measure analysis was performed for the variables and circulating Epo levels were compared between the IVF group and early OHSS. Furthermore, related growth factors, vascular endothelial growth factor (VEGF) and hypoxia-inducible factor-1 (HIF-1) were analysed from subgroup of women to test for correlation with Epo.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>During IVF, circulating Epo increased from natural mid-luteal phase to stimulated mid-luteal phase (median 9.5; 95% CI 7.2\u201313.4 IU\/L and 12.5; 10.3\u201313.4 IU\/L; <jats:italic>p<\/jats:italic> = 0.003). In cycles resulting in pregnancy, Epo level decreased 14 days after oocyte pick-up (OPU) and remained low thereafter. In cycles not resulting in pregnancy, Epo level increased again 35 days after OPU. Follicle fluid Epo concentration was 1.5 times higher than the serum concentration (median 15.4; 95% CI 10.4\u201319.2 IU\/L vs. 10.2; 8.8\u201312.7; <jats:italic>p<\/jats:italic> = 0.006). There was no difference in circulating Epo concentration between early OHSS and uncomplicated IVF. Circulating Epo did not correlate with VEGF or HIF-1.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Circulating Epo levels fluctuate during IVF cycle. We hypothesise this may suggest Epo\u2019s involvement in ovarian physiology and angiogenesis. However, Epo was not a clinical marker for OHSS.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12958-023-01178-3","type":"journal-article","created":{"date-parts":[[2024,1,20]],"date-time":"2024-01-20T00:02:21Z","timestamp":1705708941000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Serum erythropoietin level is increased during stimulation for IVF but not in OHSS"],"prefix":"10.1186","volume":"22","author":[{"given":"Merituuli","family":"Rekola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kati","family":"Korhonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Unkila-Kallio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Alfthan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vedran","family":"Stefanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aila","family":"Tiitinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomi S.","family":"Mikkola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Savolainen-Peltonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,20]]},"reference":[{"issue":"2","key":"1178_CR1","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1152\/physrev.1992.72.2.449","volume":"72","author":"W Jelkmann","year":"1992","unstructured":"Jelkmann W. Erythropoietin: structure, control of production, and function. Physiol Rev. 1992;72(2):449\u201389.","journal-title":"Physiol Rev"},{"issue":"1","key":"1178_CR2","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/j.1365-2141.2008.07014.x","volume":"141","author":"MO Arcasoy","year":"2008","unstructured":"Arcasoy MO. The non-haematopoietic biological effects of erythropoietin. Br J Haematol. 2008;141(1):14\u201331.","journal-title":"Br J Haematol"},{"issue":"10","key":"1178_CR3","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1046\/j.1365-2362.2003.01245.x","volume":"33","author":"D Ribatti","year":"2003","unstructured":"Ribatti D, Vacca A, Roccaro AM, Crivellato E, Presta M. Erythropoietin as an angiogenic factor. Eur J Clin Invest. 2003;33(10):891\u20136.","journal-title":"Eur J Clin Invest"},{"issue":"11","key":"1178_CR4","first-page":"1035","volume":"52","author":"C Caccamo","year":"2007","unstructured":"Caccamo C, Nostro L, Giorgianni G, Mondello S, Crasci E, Frisina N, et al. Behavior of vascular endothelial growth factor and erythropoietin throughout the menstrual cycle in healthy women. J Reprod Med. 2007;52(11):1035\u20139.","journal-title":"J Reprod Med"},{"issue":"3","key":"1178_CR5","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S0020-7292(96)02769-5","volume":"55","author":"S Makinoda","year":"1996","unstructured":"Makinoda S, Mikuni M, Sogame M, Kobamatsu Y, Furuta I, Yamada H, et al. Erythropoietin, granulocyte-colony stimulating factor, interleukin-1 beta and interleukin-6 during the normal menstrual cycle. Int J Gynaecol Obstet. 1996;55(3):265\u201371.","journal-title":"Int J Gynaecol Obstet"},{"issue":"5","key":"1178_CR6","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1093\/molehr\/8.5.441","volume":"8","author":"R Yokomizo","year":"2002","unstructured":"Yokomizo R, Matsuzaki S, Uehara S, Murakami T, Yaegashi N, Okamura K. Erythropoietin and erythropoietin receptor expression in human endometrium throughout the menstrual cycle. Mol Hum Reprod. 2002;8(5):441\u20136.","journal-title":"Mol Hum Reprod"},{"issue":"39","key":"1178_CR7","doi-asserted-by":"publisher","first-page":"25381","DOI":"10.1074\/jbc.273.39.25381","volume":"273","author":"Y Yasuda","year":"1998","unstructured":"Yasuda Y, Masuda S, Chikuma M, Inoue K, Nagao M, Sasaki R. Estrogen-dependent production of erythropoietin in uterus and its implication in uterine angiogenesis. J Biol Chem. 1998;273(39):25381\u20137.","journal-title":"J Biol Chem"},{"issue":"2 Suppl 2","key":"1178_CR8","first-page":"215","volume":"106","author":"Y Yasuda","year":"2001","unstructured":"Yasuda Y, Fujita Y, Musha T, Tanaka H, Shiokawa S, Nakamatsu K, et al. Expression of erythropoietin in human female reproductive organs. Ital J Anat Embryol. 2001;106(2 Suppl 2):215\u201322.","journal-title":"Ital J Anat Embryol"},{"issue":"11","key":"1178_CR9","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1093\/carcin\/23.11.1797","volume":"23","author":"Y Yasuda","year":"2002","unstructured":"Yasuda Y, Fujita Y, Masuda S, Musha T, Ueda K, Tanaka H, et al. Erythropoietin is involved in growth and angiogenesis in malignant tumours of female reproductive organs. Carcinogenesis. 2002;23(11):1797\u2013805.","journal-title":"Carcinogenesis"},{"issue":"9","key":"1178_CR10","first-page":"1470","volume":"22","author":"V Stefanovic","year":"2012","unstructured":"Stefanovic V, Pakarinen P, Alfthan H, Stenman U-H, Leminen A, Pociuviene J, et al. Erythropoietin is detectable in the Ascitic Fluid in patients with ovarian tumors. Int J Gynecol Cancer. 2012;22(9):1470\u20133.","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"1178_CR11","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.fertnstert.2005.07.1292","volume":"85","author":"EG Papanikolaou","year":"2006","unstructured":"Papanikolaou EG, Pozzobon C, Kolibianakis EM, Camus M, Tournaye H, Fatemi HM, et al. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles. Fertil Steril. 2006;85(1):112\u201320.","journal-title":"Fertil Steril"},{"issue":"9","key":"1178_CR12","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1093\/humrep\/dew149","volume":"31","author":"P Humaidan","year":"2016","unstructured":"Humaidan P, Nelson SM, Devroey P, Coddington CC, Schwartz LB, Gordon K, et al. Ovarian hyperstimulation syndrome: review and new classification criteria for reporting in clinical trials. Hum Reprod. 2016;31(9):1997\u20132004.","journal-title":"Hum Reprod"},{"issue":"3","key":"1178_CR13","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/S0015-0282(00)00670-1","volume":"74","author":"E Geva","year":"2000","unstructured":"Geva E, Jaffe RB. Role of vascular endothelial growth factor in ovarian physiology and pathology. Fertil Steril. 2000;74(3):429\u201338.","journal-title":"Fertil Steril"},{"key":"1178_CR14","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.ejogrb.2016.10.051","volume":"207","author":"KVM Korhonen","year":"2016","unstructured":"Korhonen KVM, Savolainen-Peltonen HM, Mikkola TS, Tiitinen AE, Unkila-Kallio LS. C-reactive protein response is higher in early than in late ovarian hyperstimulation syndrome. Eur J Obstet Gynecol Reprod Biol. 2016;207:162\u20138.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"6","key":"1178_CR15","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1007\/s00404-020-05556-9","volume":"301","author":"K Korhonen","year":"2020","unstructured":"Korhonen K, Unkila-Kallio L, Alfthan H, H\u00e4m\u00e4l\u00e4inen E, Tiitinen A, Mikkola T, et al. Plasma pentraxin 3 is higher in early ovarian hyperstimulation syndrome than in uncomplicated in vitro fertilization cycle of high-risk women. Arch Gynecol Obstet. 2020;301(6):1569\u201378.","journal-title":"Arch Gynecol Obstet"},{"issue":"1","key":"1178_CR16","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/S1472-6483(10)60042-9","volume":"19","author":"A Golan","year":"2009","unstructured":"Golan A, Weissman A. A modern classification of OHSS. Reprod Biomed Online. 2009;19(1):28\u201332.","journal-title":"Reprod Biomed Online"},{"issue":"3","key":"1178_CR17","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1677\/joe.0.1680409","volume":"168","author":"SE Dickson","year":"2001","unstructured":"Dickson SE, Bicknell R, Fraser HM. Mid-luteal angiogenesis and function in the primate is dependent on vascular endothelial growth factor. J Endocrinol. 2001;168(3):409\u201316.","journal-title":"J Endocrinol"},{"issue":"9","key":"1178_CR18","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1002\/mrd.20878","volume":"75","author":"H Yamashita","year":"2008","unstructured":"Yamashita H, Kamada D, Shirasuna K, Matsui M, Shimizu T, Kida K, et al. Effect of local neutralization of basic fibroblast growth factor or vascular endothelial growth factor by a specific antibody on the development of the corpus luteum in the cow. Mol Reprod Dev. 2008;75(9):1449\u201356.","journal-title":"Mol Reprod Dev"},{"issue":"3","key":"1178_CR19","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/S0015-0282(98)00221-0","volume":"70","author":"P Giovanni Artini","year":"1998","unstructured":"Giovanni Artini P, Fasciani A, Monti M, Luisi S, D\u2019Ambrogio G, Genazzani AR. Changes in vascular endothelial growth factor levels and the risk of ovarian hyperstimulation syndrome in women enrolled in an in vitro fertilization program. Fertil Steril. 1998;70(3):560\u20134.","journal-title":"Fertil Steril"},{"issue":"1","key":"1178_CR20","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1182\/blood.V78.1.89.89","volume":"78","author":"Y Beguin","year":"1991","unstructured":"Beguin Y, Lipscei G, Thoumsin H, Fillet G. Blunted erythropoietin production and decreased erythropoiesis in early pregnancy. Blood. 1991;78(1):89.","journal-title":"Blood"}],"container-title":["Reproductive Biology and Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12958-023-01178-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12958-023-01178-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12958-023-01178-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,20]],"date-time":"2024-01-20T00:02:26Z","timestamp":1705708946000},"score":1,"resource":{"primary":{"URL":"https:\/\/rbej.biomedcentral.com\/articles\/10.1186\/s12958-023-01178-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,20]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1178"],"URL":"https:\/\/doi.org\/10.1186\/s12958-023-01178-3","relation":{},"ISSN":["1477-7827"],"issn-type":[{"value":"1477-7827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,20]]},"assertion":[{"value":"12 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted according to the Declaration of Helsinki, with informed consent from the participants, and received approval from the Helsinki University Ethics Committee prior to its start.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HS-P has been a member of the advisory board of Ferring Pharmaceuticals and a consultant to Merck and Orion.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14"}}